Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

USTAALIOGLU B. O. , BILICI A., ERCAN S., ORCUN A., SEKER M., OZKAN A., USTAALIOGLU R., Gumus M.

doi:10.1007/s12094-012-0808-0

Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

USTAALIOGLU B. O. , BILICI A., ERCAN S., ORCUN A., SEKER M., OZKAN A., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.14, ss.356-361, 2012

Cilt numarası: 14 Konu: 5
Basım Tarihi: 2012
Doi Numarası: 10.1007/s12094-012-0808-0
Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
Sayfa Sayısı: ss.356-361

Özet

M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced non-small-cell lung cancer (NSCLC) compared with those in a healthy group.